InFlectis
Company Details
About: InFlectis BioScience is a private clinical-stage company aiming to target and modulate interactions between proteins involved in key human pathophysiological processes. The company is developing IFB-088 (INN: icerguastat), which specifically targets the Integrated Stress Response (ISR).
Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of diseases affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation. IFB-088 is currently in phase 2 trial to treat ALS.
Company History
InFlectis BioScience has been founded by Dr. Philippe GUEDAT on August 30, 2013. He discovered IFB-088 (INN: icerguastat) in collaboration with an academic team at the MRC Laboratory of Molecular Biology (LMB) in Cambridge UK.
Dr Philippe GUEDAT was awarded at the 2013 and 2014 National Competition of Business Startups using Innovative Technologies by the Ministry of Research in France.
- 2013: Prize of Emergence section: €50k
https://data.enseignementsup-recherche.gouv.fr/explore/dataset/fr-esr-laureats-concours-national-i-lab/table/?refine.annee_de_concours=2013&refine.region=Pays+de+la+Loire
- 2014: Prize of Creation-Development section: €300k
https://data.enseignementsup-recherche.gouv.fr/explore/dataset/fr-esr-laureats-concours-national-i-lab/table/?refine.region=Pays+de+la+Loire&refine.annee_de_concours=2014
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
InFlectis | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.